¹¹C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction

Mohammed Haseebuddin¹, Farrokh Dehdashti^{2,3}, Barry A. Siegel^{2,3}, Jingxia Liu⁴, Elizabeth B. Roth¹, Kenneth G. Nepple¹, Cary L. Siegel^{2,5}, Keith C. Fischer³, Adam S. Kibel^{1,2}, Gerald L. Andriole^{1,2}, and Tom R. Miller^{+2,3}

¹Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri; ²Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; ³Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; ⁴Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri; and ⁵Divison of Diagnostic Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

Despite early detection programs, many patients with prostate cancer present with intermediate- or high-risk disease. We prospectively investigated whether ¹¹C-acetate PET/CT predicts lymph node (LN) metastasis and treatment failure in men for whom radical prostatectomy is planned. Methods: 107 men with intermediate- or high-risk localized prostate cancer and negative conventional imaging findings underwent PET/CT with ¹¹C-acetate. Five underwent LN staging only, and 102 underwent LN staging and prostatectomy. PET/CT findings were correlated with pathologic nodal status. Treatment-failure-free survival was estimated by the Kaplan-Meier method. The ability of PET/CT to predict outcomes was evaluated by multivariate Cox proportional hazards analysis. Results: PET/CT was positive for pelvic LN or distant metastasis in 36 of 107 patients (33.6%). LN metastasis was present histopathologically in 25 (23.4%). The sensitivity, specificity, and positive and negative predictive values of PET/CT for detecting LN metastasis were 68.0%, 78.1%, 48.6%, and 88.9%, respectively. Treatment failed in 64 patients: 25 with metastasis, 17 with a persistent postprostatectomy prostate-specific antigen level greater than 0.20 ng/mL, and 22 with biochemical recurrence (prostatespecific antigen level > 0.20 ng/mL after nadir) during followup for a median of 44.0 mo. Treatment-failure-free survival was worse in PET-positive than in PET-negative patients (P < 0.0001) and in those with false-positive than in those with true-negative scan results (P < 0.01), suggesting that PET may have demonstrated nodal disease not removed surgically or identified pathologically. PET positivity independently predicted failure in preoperative (hazard ratio, 3.26; P < 0.0001) and postoperative (hazard ratio, 3.07; P = 0.0001) multivariate models. Conclusion: In patients planned for or completing prostatectomy, ¹¹C-acetate PET/CT detects LN metastasis not identified by conventional imaging and independently predicts treatment-failure-free survival.

Received Jul. 11, 2012; revision accepted Nov. 26, 2012.

For correspondence or reprints contact: Farrokh Dehdashti, Washington University School of Medicine, 510 S. Kingshighway Blvd., Box 8223, St. Louis, MO 63105.

[†]Deceased.

Published online Mar. 7, 2013.

Key Words: prostatic cancer; PET; acetate; cancer staging; lymphatic metastasis

J Nucl Med 2013; 54:699–706 DOI: 10.2967/jnumed.112.111153

A lthough many patients in the United States with newly diagnosed prostate cancer have low-risk disease, 40%-50% have intermediate- or high-risk localized disease (1,2). Up to 20% of these patients have metastatic disease, usually in lymph nodes (LNs). Identification of LN involvement is important for treatment planning (3,4). These patients typically undergo CT or MR imaging. However, neither is sensitive for detecting nodal metastasis unless the nodes are enlarged (4). In a recent meta-analysis, the sensitivity of CT and MR imaging was 39%-42% for detecting pelvic LNs (5). MR imaging with ultrasmall superparamagnetic iron oxide contrast material (which is not available in the United States) and diffusion-weighted MR imaging appear to have improved sensitivity (6), but experience is still limited.

Because of the unreliability of imaging, nomograms based on clinical parameters, such as prostate-specific antigen (PSA), T stage, and Gleason score, are used to estimate the risk of nodal metastasis (3,7,8) and may justify omission of lymphadenectomy in patients with an estimated risk of less than 5% since there is an 8%–20% complication rate for lymphadenectomy (9,10). This approach is not ideal, however, as in some cases the disease will be under-staged.

PET allows for detection of characteristic biochemical attributes of malignant cells and is not dependent on size criteria alone. PET with ¹⁸F-FDG effectively stages many cancers but has limited utility for initial staging of prostate cancer because urinary excretion may obscure nodal uptake; additionally, most prostate cancers have low rates of glucose metabolism, and ¹⁸F-FDG uptake is similar in prostate cancer, benign prostatic enlargement, and inflammation (*11,12*).

E-mail: dehdashtif@mir.wustl.edu

COPYRIGHT \circledcirc 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Because of these limitations, other radiopharmaceuticals have been investigated for prostate cancer imaging, including ¹¹C-acetate (11,13). Acetate enters the biochemical pathways of fatty acid metabolism, which are consistently upregulated in prostate cancer cell lines (14), and ¹¹C-acetate has minimal urinary excretion (15). Although multiple studies have demonstrated promising results with ¹¹C-acetate PET for diagnosing local and distant disease after initial treatment failure (16–20), less is known about its value for initial prostate cancer staging (21).

The purpose of this prospective study was to investigate PET/CT with ¹¹C-acetate for nodal staging and as a biomarker for prediction of treatment failure in patients with newly diagnosed intermediate- or high-risk disease, for whom radical prostatectomy was planned and conventional staging was negative for metastasis.

MATERIALS AND METHODS

This study was conducted within a larger prospective study (http://www.clinicaltrials.gov, NCT00121212) investigating ¹¹C-acetate PET/CT for staging of disease in patients with newly diagnosed prostate cancer for whom radical prostatectomy or radiation therapy was planned. The study was approved by the institutional review board at Washington University. All subjects gave written informed consent.

Patients and Eligibility Criteria

The patient flow diagram of the study is shown in Figure 1. From October 2003 to November 2009, 177 men with newly diagnosed biopsy-proved prostate cancer who were judged to be at intermediate or high risk for nodal metastasis and had negative abdominopelvic CT (or pelvic MR imaging) and bone scintigraphy findings underwent ¹¹C-acetate PET/CT. Intermediate- or high-risk patients were defined as those with a Gleason score of 7 and a PSA level of at least 10 ng/mL, a Gleason score of at least 8 and any PSA level, or any Gleason score and a PSA level of more than 20 ng/mL. Patients were excluded from this analysis if they elected to have primary radiation therapy (n = 59), had hormonal therapy before PET/CT (n = 7), or were lost to followup after PET/CT (n = 4). The remaining 107 patients for whom radical prostatectomy was planned comprise the cohort of this report. All these patients underwent CT (rather than MR imaging) for preenrollment staging.

¹¹C-Acetate PET/CT

PET/CT was performed on either a Biograph Duo (n = 110) or a Biograph 40 (n = 67) scanner (Siemens). ¹¹C-acetate, 1.48 GBq for studies on the Biograph Duo and 0.74 GBq for studies on the Biograph 40, was administered intravenously. Approximately 10–15 min after injection, a 10- to 20-s CT topogram was obtained from the skull base through the pelvis. On the basis of the topogram, the tube current for the CT scan was adjusted so that the effective current was between 95 and 111 mAs. The tube voltage was 130 kVp (Biograph Duo) or 120 kVp (Biograph 40). Reconstructed images were of slices 5 mm thick. Immediately after the CT scan, emission images beginning at the pelvis and proceeding cranially were obtained. Emission images ranged from 2 to 5 min in duration for each of the 6–8 bed positions.




FIGURE 1. Patient flow diagram.

Image Interpretation

Each PET/CT study was reviewed preoperatively by an experienced nuclear radiologist and a genitourinary radiologist, first independently and then jointly. Their consensus interpretation was used for this analysis. The radiologists were aware of the diagnosis of prostate cancer, Gleason score, and PSA level, as defined by the study eligibility criteria. Considering the normal biodistribution of ¹¹C-acetate, the radiologists graded the presence or absence of metastasis on PET/CT imaging (pelvic or distant LN or distant organ metastasis) on a 5-point ordinal scale from 0 to 4, where 0 is definitely normal and 4 is definitely abnormal. Scans graded 2–4 were considered PET-positive. In addition, all PET images were evaluated semiquantitatively by determination of the maximum standardized uptake value within the prostate gland.

Treatment and Pathologic Evaluation

To allow for assessment of the impact of PET on patient management, neither patients nor their treating physicians were masked to the results of ¹¹C-acetate PET/CT. The information was available for clinical decision making, such that patients could be diverted from prostatectomy if PET demonstrated metastasis that was confirmed before surgery by biopsy. The management of each patient was documented by medical record review.

The surgical approach, laparoscopic or open, and lymphadenectomy boundaries were left to the discretion of the surgeon. However, lymphadenectomy involved, at a minimum, removal of nodes within the obturator fossae (external iliac artery anteriorly, pelvic sidewall laterally, obturator nerve inferiorly, and Cooper ligament distally). Nodal metastatic status was based on the pathology findings from final biopsy or lymphadenectomy. The pathologists did not know the results of PET/CT.

Follow-up and Assessment of Treatment Failure

Patients were followed every 3–6 mo postoperatively with physical examination and serum PSA measurement.

Treatment failure was defined as one of the following events: pathologic diagnosis of metastasis by biopsy or surgery, a persistently detectable PSA level of more than 0.20 ng/mL at least 4 wk after surgery, or subsequent biochemical recurrence with a PSA level of more than 0.20 ng/mL and rising (with the failure event dated to the first occurrence). The time to treatment failure was defined as the time from PET/CT until the failure event. Patients given adjuvant therapy without biochemical recurrence, because of high pathologic T stage or positive margins in the prostatectomy specimen, were not considered to have experienced treatment failure. For assessment of treatment-failure–free survival, patients who did not have treatment failure were censored at the last follow-up date. Seven patients died after either their date of disease progression or their last follow-up visit; thus, none of these deaths was considered to be within the study interval.

Statistical Analysis

The ¹¹C-acetate PET/CT findings of LN metastasis were correlated with the histologic findings on a per-patient basis to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for PET detection of nodal metastasis. Continuous and categoric variables between PET-positive and PET-negative patients (with respect to nodal or distant metastasis) were compared by a Kruskal–Wallis test and the Fisher exact test, respectively. Treatment-failure–free survival for PET-positive and PET-negative patients was examined using Kaplan–Meier analysis and a log-rank test. Univariate predictors of treatment failure included biopsy Gleason score, percentage biopsy core–positive, PSA level, clinical stage, PET positivity, prostate maximum standardized uptake value, pathologic Gleason score, pathologic stage, and surgical margin status. Preoperative and postoperative multivariate Cox proportional hazards analyses evaluated the independent predictive ability of PET status while controlling for these covariates. The assumption of proportionality was tested and met for Cox analysis. A *P* value of less than 0.05 was considered statistically significant for all study outcomes, and all statistical tests were 2-sided. SAS software, version 9 (SAS Institute Inc.), was used to perform statistical analyses.

RESULTS

The demographic, clinical, and pathologic data of the patients are summarized in Table 1. Median age was 61 y, and median PSA level was 11.8 ng/mL. Clinical T stage was T1 in 66.7% of patients, and biopsy Gleason scores were 8–10 in 58.9%.

¹¹C-Acetate PET/CT Findings

A representative scan with ¹¹C-acetate PET/CT–positive findings in both the prostate gland and a pelvic LN is shown in Figure 2.

Parameter	Total	PET-positive for metastasis	PET-negative for metastasis	<i>P</i> *
Patients (n)	107	36	71	
Age (y)				0.9544
Median	61	61.5	61	
Range	46–80	47–78	46–80	
PSA (ng/mL)				
Median	11.8	11.25	11.9	0.355
Range	1.4–225.4	1.4-82.4	2.9–225.4	
Clinical stage (n)	105*	35	70	
T1	70 (66.7%)	21 (60.0%)	49 (70.0%)	0.290
T2	34 (32.4%)	13 (37.1%)	21 (30.0%)	
Т3	1 (0.9%)	1 (2.9%)	0 (0.0%)	
Biopsy Gleason score (n)	107	36	71	
6	6 (5.6%)	1 (2.78%)	5 (7.04%)	0.836
7	38 (35.5%)	13 (36.11%)	25 (35.21%)	
8–10	63 (58.9%)	22 (61.11%)	41 (57.75%)	
Prostatectomy pathology Gleason score (n)	102 [†]	31	71	
6	6 (5.9%)	1 (3.23%)	5 (7.0%)	0.034
7	53 (52.0%)	11 (35.48%)	42 (59.2%)	
8–10	43 (42.1%)	19 (61.3%)	24 (33.8%)	
Pathologic stage (n)	102 [†]	31	71	
T2	41 (40.2%)	7 (22.58%)	34 (47.89%)	0.027
ТЗа	28 (27.5%)	9 (29.03%)	19 (26.76%)	
T3b	32 (31.4%)	14 (45.16%)	18 (25.35%)	
T4	1 (1.0%)	1 (3.23%)	0 (0.00%)	
Time from PET/CT to surgery (d)	106	35	71	
Median	13	13	14	0.355
Range	1–290	1–290	1–79	

 TABLE 1

 Clinical and Pathologic Demographic Information

*Data unavailable in 2 patients.

[†]102 patients underwent prostatectomy whereas 5 underwent LN sampling or biopsy only.




FIGURE 2. Representative ¹¹C-acetate CT (A), PET/CT (B), and PET (C) images of patient with prostate cancer in 4 quadrants and unsuspected LN metastasis. Gleason score was 8, and PSA level was 6.4 ng/mL. Diffusely increased ¹¹C-acetate uptake was noted within prostate gland and was most intense in right lobe (maximum standardized uptake value, 8.4; short arrow). Long arrows point to normal-sized left external iliac LN, which was proved to harbor metastatic disease.

On the ¹¹C-acetate PET/CT images, focally or diffusely increased activity, presumably representing abnormal tracer uptake in the primary tumor, was recorded in the prostate gland in 103 of the 107 patients (96.3%). The mean maximum standardized uptake value (\pm SD) in these 103 prostate glands was 5.4 \pm 1.8. In no instance was ¹¹C-acetate PET/CT positive in LNs but negative in the prostate gland.

¹¹C-acetate PET/CT demonstrated metastasis in 36 (33.6%) of 107 patients. Of these, 35 had LN metastasis (32 in pelvic LNs only, 2 in pelvic LNs and a distant node [1 supraclavicular and 1 paratracheal], and 1 in pelvic LNs and bone), and 1 patient had bone metastasis only. The 2 patients with PET findings of bone metastasis were negative for skeletal foci on MR imaging and underwent prostatectomy as planned; both were considered to have experienced treatment failure on the basis of a persistently increased PSA level after prostatectomy. As is shown in Table 1, the 36 PET-positive patients were more likely than the 71 PET-negative patients to have higher prostatectomy Gleason scores and a higher pathologic stage but otherwise had similar clinical features.

Pathology Findings

One-hundred two patients underwent prostatectomy and lymphadenectomy, and 5 underwent LN sampling only (1 with fine-needle aspiration of distant nodes only and 4 with pelvic lymphadenectomy). Four of the 5 patients with only nodal sampling had metastasis and were defined as having had a treatment failure. The remaining patient had negative pathology findings but opted for radiation therapy (and was excluded from the treatment failure analysis). Of the 102 patients undergoing prostatectomy and lymphadenectomy, 21 (20.6%) had nodal metastasis.

¹¹C-Acetate PET/CT LN Staging

On a per-patient basis, the overall sensitivity, specificity, PPV, and NPV of PET/CT for detection of LN metastasis were 68.0%, 78.1%, 48.6%, and 88.9%, respectively (Table 2).

Treatment-Failure–Free Survival Analysis

Failure Events. The cohort for treatment failure analysis consisted of 106 patients; 1 patient with positive PET findings had a negative result from LN biopsy, opted for radiotherapy, and was excluded from the failure analysis. Treatment failure occurred in 64 of the 106 patients: 4 diverted from prostatectomy with biopsy-confirmed metastasis, 21 with confirmed nodal metastasis at lymphadenectomy, and 17 with persistently detectable PSA after prostatectomy. Of the remaining 64 patients, 22 had biochemical recurrence during a median follow-up of 44.0 mo (range, 1.2–93.5 mo). Three patients received adjuvant therapy for positive margins without biochemical recurrence and were not considered to have experienced treatment failure at that time.

 TABLE 2

 Correlation of PET/CT and Pathologic Results for Nodal Metastasis (Per-Patient Basis)

	Pathology		
PET/CT	LN-positive	LN-negative	Total
LN-positive	17	18	35
LN-negative	8	64	72
Total	25	82	107

Sensitivity = 68.0% (95% confidence interval, 46.5%-85.1%); specificity = 78.1% (67.5%-86.4%); PPV = 48.6% (31.4%-66.0%); NPV = 88.9% (79.3%-95.1%).

Univariate Analysis. On univariate analysis, factors predicting treatment failure are shown in Table 3. PET/CT positivity for any site of metastasis was significantly associated with poorer treatment-failure–free survival on univariate analysis (hazard ratio, 3.830; P < 0.001) (Fig. 3). The 3-y failure probabilities of PET-negative and PET-positive patients are 51% and 82%, respectively. The median treatment-failure–free survival for PET-positive patients was 1.3 mo, whereas that for PET-negative patients was 31.5 mo. Patients with false-positive PET/CT findings (relative to the pathologic reference standard) had worse treatment-failure–free survival than patients with true-negative PET/CT findings (P < 0.01), suggesting that PET/CT may have demonstrated nodal disease not removed at surgery or not identified in the pathologic specimen (Fig. 4).

Multivariate Analysis. On the preoperative multivariate Cox proportional hazards model (Table 4), PET metastasis was significantly associated with a 3.26-fold (95% confidence interval, 1.86–5.72; P < 0.0001) increased risk of treatment failure while controlling for other known preop-

erative factors (PSA, clinical stage, biopsy Gleason score, and percentage cores positive).

On the postoperative multivariate Cox proportional hazards model (Table 5), PET metastasis was significantly associated with a 3.07-fold (95% confidence interval, 1.73–5.46; P = 0.0001) increased risk of treatment failure while controlling for other postoperative factors (PSA, pathology stage, pathology Gleason score, and surgical margins).

DISCUSSION

Accurate LN staging is important for management of patients with newly diagnosed prostate cancer. CT, the current standard imaging modality, relies primarily on nodal size to identify nodal metastasis and is neither sufficiently sensitive nor sufficiently specific (22). Conventional MR imaging and diffusion-weighted MR imaging have similar limitations (23).

Our study indicated that in patients with negative CT findings, ¹¹C-acetate PET/CT can detect LN metastasis with a sensitivity and specificity of 68% and 78%, respectively. Although the PPV of PET/CT based on pathologic correlation was only 49%, the Cox proportional hazards model for predicting treatment failure showed that patients with an apparent false-positive PET result had a significantly worse prognosis than did those with true-negative PET results, suggesting that the relatively low PPV might be due to inadequate lymphadenectomy or lack of pathologic identification of positive nodes.

Several other studies using either ¹¹C-acetate PET or ¹¹C-choline PET have confirmed the potential of PET for diagnosing metastatic prostate cancer (*13*). Neither tracer has significant urinary excretion, and both enter into the biochemical pathways of fatty acid metabolism, which are

Variable	<i>n</i> *	Hazard ratio	Р
PET metastasis (any site)	106	3.83 (2.30, 6.38)	<0.0001
Clinical Gleason score	106		0.1092
6 vs. 7		0.46 (0.11, 1.97)	
(8, 9, 10) vs. 7		1.51 (0.89, 2.55)	
Percentage cores positive	101	1.01 (1.00, 1.02)	0.0140
PSA (ng/mL)	106	1.01 (1.00, 1.01)	0.0563
Clinical stage (cT2 vs. cT1c)	103	1.39 (0.814, 2.36)	0.2294
Standardized uptake value (primary prostate cancer)	106	1.11 (0.97, 1.26)	0.1285
Pathology Gleason score	102		< 0.0001
6 vs. 7		0.26 (0.04, 1.96)	
(8, 9, 10) vs. 7		2.82 (1.67, 4.76)	
Pathology stage	101		< 0.0001
3a vs. 2		2.93 (1.39, 6.20)	
3b vs. 2		9.15 (4.47, 18.70)	
Surgical margins	102	2.56 (1.50, 4.37)	0.0006

TABLE 3 Univariate Model for Predicting Treatment Failure

*Number of patients for whom variable was available.

Data in parentheses are 95% confidence intervals.




FIGURE 3. Treatment-failure–free survival of patients who were PET-positive and PET-negative for metastatic disease at any site.

consistently upregulated in prostate cancer cell lines (13). ¹¹C-choline is incorporated into cellular membranes as phosphatidylcholine through overexpression of fatty acid synthetase, whereas ¹¹C-acetate participates in cytoplasmic lipid synthesis, which is believed to be increased in tumors (24).

Compared with other studies using ¹¹C-acetate PET, ours uniquely evaluated the staging of newly diagnosed prostate cancer prospectively by comparing PET with pathologic nodal status as the reference standard. Multiple other studies have evaluated the effectiveness of ¹¹C-acetate PET in prostate cancer (14-21,25). However, most of these studies have focused on patients with recurrent disease, have included heterogeneous patient populations (local recurrence, nodal disease, bone or visceral metastasis) or reference standards, and have been limited by small sample sizes. These studies did not have extensive confirmatory pathologic evaluation of PET-positive disease and relied on the tracer uptake value or follow-up findings to infer that PET positivity represents a true-positive finding (21,25).

¹¹C-choline PET has been studied more extensively for preoperative LN staging. De Jong et al. (26), in examining 67 patients with newly diagnosed prostate cancer who underwent ¹¹C-choline PET/CT, found a sensitivity of 80% and specificity of 96% for detecting nodal metastasis. However, only 24 patients in the study underwent lymphadenectomy, and scan results were assumed to be true-negative on the basis of the clinical scenario in 14 without pathology or to be true-positive in 10 patients who declined surgery and had




FIGURE 4. Treatment-failure–free survival stratified by PET/CT results referenced to nodal pathology results.

TABLE 4Preoperative Multivariate Cox Proportional Hazards Modelfor Predicting Treatment Failure (n = 98)

Variable	Hazard ratio	Р
PET metastasis (any site)	3.26 (1.86, 5.72)	< 0.0001
PSA (ng/mL)	1.01 (1.00, 1.02)	0.0043
Clinical stage (cT2 vs. cT1c)	1.16 (0.66, 2.06)	0.6065
Clinical Gleason score		0.0199
6 vs. 7	0.76 (0.17, 3.48)	
(8, 9, 10) vs. 7	2.14 (1.20, 3.81)	
Percentage cores positive	1.01 (1.00, 1.02)	0.1089
Data in parentheses are 95% o	confidence intervale	

gross disease seen on preoperative CT scans. Approximately half the patients with nodal metastasis had lymphadenopathy already detectable by standard imaging (CT or MR) and therefore would have been excluded from our study. Also, the patients appeared to be at higher risk for nodal metastasis than ours, with an average PSA level of 34 (range, 3-500) ng/mL, a PSA level greater than 20 ng/mL in 60% of patients, and cT2/3 disease in 75%. Schiavina et al. (27), in examining the ¹¹C-choline PET images of 57 patients with newly diagnosed prostate cancer who had previous negative results on bone scintigraphy and underwent extended pelvic lymphadenectomy, found a sensitivity of 60% and specificity of 97.6%. This sensitivity was similar to that found in our study with ¹¹C-acetate PET (60% vs. 68%), whereas the specificity and PPV were higher than in our study (97.6% vs. 78% and 90% vs. 48%, respectively). However, their patient population overall was at lower risk for nodal metastasis than our population and included more patients with biopsy Gleason scores of 5 or 6 (22 of 57) and fewer with biopsy Gleason scores of 8-10 (8 of 57), likely explaining their high specificity rates. Their higher PPV may also reflect the use of a standardized approach to extended pelvic lymphadenectomy rather than allowing for surgical discretion, as in our study. Whether the differences in sensitivity, specificity, and PPV between these studies are also attributable to differences in performance of these 2 tracers is unclear. Besides differential uptake of ¹¹C-acetate intracellularly and ¹¹C-choline in the cellular membrane, clinically relevant distinctions between these 2 tracers have not been elucidated at this time. However, a single small study indicated that they may be equivalent (28). Similar results for LN metastasis detection have been reported for PET/CT performed with ¹⁸F-fluorocholine derivatives (29).

In addition to providing anatomic localization of metastatic disease, the results of ¹¹C-acetate PET/CT were also found in our study to be independently predictive of failure of planned or completed radical prostatectomy in both preoperative and postoperative multivariate models. To our knowledge, this was the first study in which the results of initial staging PET were correlated to treatment failure in prostate cancer patients. Most of the patients with PET/CT-positive

disease experienced treatment failure early, either immediately perioperatively or within a few months of surgery. By 1 y, 79% of PET/CT-positive patients had experienced treatment failure, as opposed to 26% of PET/CT-negative patients. ¹¹C-acetate PET/CT may allow for better treatment counseling in patients with high-risk prostate cancer. Knowing that their PET/CT findings were positive, 5 of our patients elected to undergo biopsy before having definitive surgery. Four of these patients were confirmed to have metastasis and received radiotherapy or hormonal therapy, sparing them the potential complications of surgery. ¹¹C-acetate PET/CT may also help to identify patients likely to benefit from multimodality therapy. Currently, studies on neoadjuvant therapy before radical prostatectomy focus on clinical parameters (PSA, biopsy Gleason score, and clinical stage) and are investigational (30,31). Although clinical parameters may identify patients with a high risk of metastasis, they do not provide confirmation of metastasis as PET/CT may.

Although our study avoided some of the pitfalls of past ¹¹C-acetate and ¹¹C-choline PET studies, it was not without limitations. First, patients and surgeons were deliberately not masked to the results of the ¹¹C-acetate PET/CT studies in order to gain an appreciation of the real-world utility of this technology, and this choice may have introduced verification bias. Second, treating urologists were allowed to individualize the limits of lymphadenectomy on the basis of, at least in part, the PET findings. This choice may have contributed to the low PPV of our PET results.

PET/CT for initial staging of prostate cancer is not without drawbacks. Because of the short half-life of ¹¹C (20 min), the widespread use of ¹¹C-acetate (and ¹¹C-choline) is largely limited to centers with on-site cyclotrons. Despite this limitation, it is of interest that ¹¹C-choline recently was approved by the U.S. Food and Drug administration at a single site for use as an adjunct for evaluation of patients with suspected recurrent prostate cancer (*32*). Newer radiopharmaceuticals labeled with ¹⁸F (half-life, 110 min) would overcome this limitation, but none has yet been commercialized (*33,34*). Additionally, the routine use of PET/CT staging

TABLE 5Postoperative Multivariate Cox Proportional HazardsModel for Predicting Treatment Failure (n = 101).

Variable	Hazard ratio	Р
PET metastasis (any site)	3.07 (1.73, 5.46)	0.0001
PSA (ng/mL)	1.00 (1.00, 1.01)	0.3722
Pathology stage 3a vs. 2 3b vs. 2	2.45 (1.07, 5.62) 8.15 (3.67, 18.11)	<0.0001
Pathology Gleason score 6 vs. 7 (8, 9, 10) vs. 7	0.31 (0.04, 2.48) 2.45 (1.39, 4.31)	0.0021
Surgical margins (positive vs. negative)	1.18 (0.64, 2.18)	0.5912

Data in parentheses are 95% confidence intervals.

would add a substantial cost to the management of prostate cancer. Only carefully designed studies can determine whether the benefits of PET/CT with ¹¹C-acetate or another radiopharmaceutical for detecting LN metastasis and predicting treatment failure outweigh the expense of the procedure. Until then, pelvic LN dissection, although invasive, remains the gold standard for diagnosing LN disease.

CONCLUSION

Although pelvic lymphadenectomy is the gold standard for diagnosing nodal metastasis, ¹¹C-acetate PET/CT is more sensitive than current imaging methods for staging of men with medium- to high-risk prostate cancer. It may guide initial treatment planning by prompting surgeons to perform a more extended pelvic lymphadenectomy. In patients for whom prostatectomy is planned or has been completed after negative findings on conventional imaging, ¹¹C-acetate PET/CT independently predicts treatment-failure–free survival.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by National Institutes of Health grants CA101734 and P30 CA091842 and the Alvin J. Siteman Cancer Center Biostatistics Core and Imaging and Response Assessment Core. No other potential conflict of interest relevant to this article was reported.

REFERENCES

- Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU Int.* 2008;101:1513–1518.
- Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–1123.
- Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–1101.
- Parker CC, Husband J, Dearnaley DP. Lymph node staging in clinically localized prostate cancer. *Prostate Cancer Prostatic Dis.* 1999;2:191–199.
- Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. *Clin Radiol.* 2008;63:387–395.
- Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. *Eur Urol.* 2009;55:761–769.
- Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. *Eur Urol.* 2006;49:1019–1026.
- Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798–1803.
- Bishoff JT, Reyes A, Thompson IM, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. *Urology*. 1995;45:270–274.
- Briganti A, Chun FK, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. *Eur Urol.* 2006;50:1006–1013.

- Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. *Eur Urol.* 2007; 51:1511–1520.
- Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with ¹⁸fluorinelabeled deoxyglucose. *J Urol.* 1996;155:994–998.
- Jadvar H. Prostate cancer: PET with ¹⁸F-FDG, ¹⁸F- or ¹¹C-acetate, and ¹⁸F- or ¹¹C-choline. J Nucl Med. 2011;52:81–89.
- Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-¹¹C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327–334.
- Seltzer MA, Jahan SA, Sparks R, et al. Radiation dose estimates in humans for ¹¹C-acetate whole-body PET. J Nucl Med. 2004;45:1233–1236.
- 16. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with ¹¹C-acetate and ¹⁸F-FDG in prostate cancer patients. *Eur J Nucl Med Mol Imaging*. 2003;30:607–611.
- Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. *Eur J Nucl Med Mol Imaging*. 2002;29:1380–1384.
- Oyama N, Akino H, Kanamaru H, et al. ¹¹C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–186.
- Oyama N, Miller TR, Dehdashti F, et al. ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555.
- Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. *Urol*ogy. 2006;67:996–1000.
- Morris MJ, Scher HI. ¹¹C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:181–184.
- Wolf JS Jr. Cher M, Dall'era M, Presti JC Jr. Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995;153:993–999.
- Budiharto T, Joniau S, Lerut E, et al. Prospective evaluation of ¹¹C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. *Eur Urol.* 2011;60:125–130.
- Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230–234.
- Albrecht S, Buchegger F, Soloviev D, et al. ¹¹C-acetate PET in the early evaluation of prostate cancer recurrence. *Eur J Nucl Med Mol Imaging*. 2007;34:185–196.
- de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by ¹¹C-choline PET. J Nucl Med. 2003;44:331–335.
- Schiavina R, Scattoni V, Castellucci P, et al. ¹¹C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. *Eur Urol.* 2008;54:392–401.
- Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of [¹¹C] acetate and [¹¹C]choline PET for detection of metastases of prostate cancer. *Nuklearmedizin*. 2003;42:25–30.
- Beheshti M, Imamovic L, Broinger G, et al. ¹⁸F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. *Radiology*. 2010;254: 925–933.
- Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. *J Urol.* 2011;186:882–887.
- Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. *Urology*. 2003;62 (suppl 1):55–62.
- U.S. Food and Drug Administration Web site. FDA news release: FDA approves production of imaging agent that helps detect prostate cancer. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm. Accessed February 25, 2013.
- Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-carboxy-5-[(6-[¹⁸F]fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [¹⁸F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. *Clin Cancer Res.* 2011; 17:7645–7653.
- Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63.